Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology

All-in-one urology laser platform
Lumenis Pulse™ 120H with MOSES™ 2.0 Technology

The MOSES 2.0 Technology advances the next generation of Lithotripsy and BPH treatments by leveraging versatility, speed and power.¹,²

- Increased Efficiency³,⁴
- Optimal Energy Delivery³,⁵
- Comprehensive Versatility for Urology Procedures
- Demonstrated Economic Value⁶,⁷

The initial controlled laser pulse separates the water, creating a pathway for a second laser sequence.

The second part of the pulse is then emitted through the initial bubble, delivering an optimized laser pulse to the target.
MOSES™ 2.0 Technology for Lithotripsy

Improving the gold standard for laser lithotripsy\(^8\)

Be it a kidney, ureteral or bladder stone, soft or hard - MOSES 2.0 Technology provides you with the speed and power you need for both ureteroscopic and percutaneous stone treatments.\(^*,3,9,10,11\)

**Efficient energy transmission for each working distance**\(^**,12\)

---

* Bench test results may not necessarily be indicative of clinical performance.
** Compared to standard holmium.
Lithotripsy Performance, Unleashed
Embrace best-in-class combination of the MOSES™ 2.0 laser and fibers

- **20% Faster procedures**
  As shown in a randomized clinical trial, the MOSES 2.0 Technology reduces procedure time by 20%, making your treatments faster and more efficient.³

- **33% Improved fragmentation efficiency**
  MOSES 2.0 Technology high precision and optimized impact on the target stone makes the most of every shot, leading to a greater ablation rate compared to regular pulses.³

- **50% Reduced retropulsion**
  The MOSES 2.0 Technology has taken retropulsion reduction to the next level, decreasing retropulsion levels by 50%.³

- **120Hz Comprehensive stone management**
  From ultra-speed stone dusting, through unprecedented pop-corning settings - MOSES 2.0 Technology offers the speed and energy you need - when you need it.
MOSES™ 2.0 Technology
Increased Efficiencies

92% greater stone ablation at same energy

42% greater stone ablation at similar power

Focus on what matters in your percutaneous approach

**Standard, Mini and UltraMini PCNL**

MOSES 2.0 Technology provides smaller stone particles compared to standard holmium, allowing you to miniaturize your percutaneous access.\(^{13-15}\)

PCNL suction handpiece

Allows for simultaneous lithotripsy and aspiration of stone fragments for control in standard PCNL.

*Bench test results may not necessarily be indicative of clinical performance.*
MOSESTM 200 D/F/L flexible fiber is designed to minimize scope deflection loss, enabling you to reach difficult-to-access stone locations.

Leave no stone behind

Smooth process, more confidence

Advanced ball-shaped tip enables a smooth initial insertion of the MOSES 200 D/F/L fiber through a flexible scope, designed to minimize potential scope damage.
HoLEP with MOSES™ 2.0 Technology:
Shifting paradigms

HoLEP provides excellent and durable clinical outcomes (PVR, Qmax, IPSS and QoL) with a reoperation rate as a result of recurrent obstruction from residual adenoma of only 0.7% at 10-year follow-up.\textsuperscript{16}

Moreover, HoLEP demonstrates better outcomes with regards to hemoglobin loss, bladder irrigation, catheterization time, hospital stay and blood transfusion.\textsuperscript{*17}

The groundbreaking MOSES 2.0 Technology offers an efficient treatment for a wide range of patients including a broad range of prostate sizes and patients treated with anticoagulants.\textsuperscript{2,18}

\*HoLEP vs. TURP

\begin{itemize}
\item 90+\% Same-day Discharge\textsuperscript{5}
\item 40\% Faster Hemostasis\textsuperscript{**5}
\item 15\% Faster Enucleation\textsuperscript{**5}
\end{itemize}

\textsuperscript{**}Compared to standard holmium.
MOSES™ 2.0 Technology for HoLEP

Versatility for different prostate sizes, patients, techniques

90+% same-day discharge, 90% same-day catheter-free success rate*
With more efficient procedures and significantly reduced blood loss – MOSES 2.0 Technology for BPH results in over 90% of patients being discharged on the same day, and same-day catheter removal has been demonstrated with a 90% success rate.2,4,5

*In select patients

Demonstrated economic value**
HoLEP with MOSES 2.0 Technology demonstrated $721 lower cost of fiber and operating room time per case, compared to standard high power HoLEP, due to lower mean operative time.7

**Randomized study of 56 patients. Assumes MOSES fibers at $119 premium to SlimLine™ fibers; cost of operating room time per minute assumed at $37.
Faster learning curve
The MOSES 2.0 Technology allows the ability to learn the HoLEP technique, and build confidence after 20 procedures supervised by an experienced urologist.\textsuperscript{21}

With faster hemostasis, MOSES 2.0 Technology for BPH can enable a tapered learning curve by providing better vision clarity and control during the procedure.\textsuperscript{5,22}

"With Moses 2.0 the learner can focus on mastering HoLEP without distractions. Minimal fiber burnback and movement, and improved hemostasis decreasing surgery interruptions and allowing for more precise laser control."

Dr. Amy E. Krambeck
Professor of Urology, Northwestern Medical

\textsuperscript{*Compared to standard holmium.}
A Powerful MOSES™ 2.0 Technology Solution for Vaporization

Higher vaporization rate and efficacy

Holmium laser vaporization of the prostate (HoLVP) with MOSES 2.0 Technology demonstrates 95% higher ablation efficiency compared to standard HoLVP, translating into time savings in the operating room.

Long-lasting results

HoLVP demonstrates durable results of 83%. Qmax improvement and 47% decrease in AUA score.

Maintain hemostasis

Holmium laser provides precise and quick vaporization of tissue with the ability to maintain hemostasis without thermal injury to tissue.

*HoLAP (ablation) was recognized and used interchangeably with HoLVP (vaporization) in the AUA guidelines through 2011 and the EAU guidelines through 2014.

**BSC Calculations: 0.91 ± 0.54 g/min vs 1.77 ± 1.41 g/min, P= 0.01

***Study of 7 years, compared to baseline, N=34.
Risk Information:
The use of MOSES Technology in Urology, enabled in the Lumenis Pulse 120H system, is contraindicated for patients who are unable to receive endoscopic treatments or are intolerant to prolonged anesthesia, as well as for resection or excision of large vascularized organs. Holmium lasers are intended solely for use by physicians trained in the use of the Ho:YAG (2.1 μm) wavelength. Incorrect treatment settings can cause serious tissue damage. The laser should be used only on tissues that are fully observable. See the system user manual for a complete list of contraindications and risks.
References


9. Data on file with Boston Scientific. Testing was performed on or behalf of BSC.


The MOSES™ 2.0 Technology is inclusive of all MOSES™ 1.0 settings and features.

Boston Scientific acquired the global surgical business of Lumenis Ltd. Lumenis Pulse™ 120H is the registered product name. Lumenis Pulse™ 120H is manufactured and sold by Boston Scientific. Lumenis is a registered trademark of Lumenis Be.

Rx only.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.